Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer
- PMID: 25789974
- PMCID: PMC4385942
- DOI: 10.1038/cddis.2015.65
Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer
Abstract
The Kruppel-like transcription factors (KLFs) 4 and 5 (KLF4/5) are coexpressed in mouse embryonic stem cells, where they function redundantly to maintain pluripotency. In mammary carcinoma, KLF4/5 can each impact the malignant phenotype, but potential linkages to drug resistance remain unclear. In primary human breast cancers, we observed a positive correlation between KLF4/5 transcript abundance, particularly in the human epidermal growth factor receptor 2 (HER2)-enriched subtype. Furthermore, KLF4/5 protein was rapidly upregulated in human breast cancer cells following treatment with the HER2/epidermal growth factor receptor inhibitor, lapatinib. In addition, we observed a positive correlation between these factors in the primary tumors of genetically engineered mouse models (GEMMs). In particular, the levels of both factors were enriched in the basal-like tumors of the C3(1) TAg (SV40 large T antigen transgenic mice under control of the C3(1)/prostatein promoter) GEMM. Using tumor cells derived from this model as well as human breast cancer cells, suppression of KLF4 and/or KLF5 sensitized HER2-overexpressing cells to lapatinib. Indicating cooperativity, greater effects were observed when both genes were depleted. KLF4/5-deficient cells had reduced basal mRNA and protein levels of the anti-apoptotic factors myeloid cell leukemia 1 (MCL1) and B-cell lymphoma-extra large (BCL-XL). Moreover, MCL1 was upregulated by lapatinib in a KLF4/5-dependent manner, and enforced expression of MCL1 in KLF4/5-deficient cells restored drug resistance. In addition, combined suppression of KLF4/5 in cultured tumor cells additively inhibited anchorage-independent growth, resistance to anoikis and tumor formation in immunocompromised mice. Consistent with their cooperative role in drug resistance and other malignant properties, KLF4/5 levels selectively stratified human HER2-enriched breast cancer by distant metastasis-free survival. These results identify KLF4 and KLF5 as cooperating protumorigenic factors and critical participants in resistance to lapatinib, furthering the rationale for combining anti-MCL1/BCL-XL inhibitors with conventional HER2-targeted therapies.
Figures





Similar articles
-
PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.Breast Cancer Res. 2015 Jun 19;17(1):86. doi: 10.1186/s13058-015-0594-z. Breast Cancer Res. 2015. PMID: 26084280 Free PMC article.
-
Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors.Breast Cancer Res Treat. 2015 Jan;149(1):91-8. doi: 10.1007/s10549-014-3227-9. Epub 2014 Dec 17. Breast Cancer Res Treat. 2015. PMID: 25515931 Free PMC article.
-
Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.Oncotarget. 2015 Feb 10;6(4):1967-80. doi: 10.18632/oncotarget.2806. Oncotarget. 2015. PMID: 25596742 Free PMC article.
-
ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy.Endocr Relat Cancer. 2016 Dec;23(12):T243-T257. doi: 10.1530/ERC-16-0360. Epub 2016 Oct 7. Endocr Relat Cancer. 2016. PMID: 27765799 Review.
-
Kruppel-like Pluripotency Factors as Modulators of Cancer Cell Therapeutic Responses.Cancer Res. 2016 Apr 1;76(7):1677-82. doi: 10.1158/0008-5472.CAN-15-1806. Epub 2016 Mar 10. Cancer Res. 2016. PMID: 26964625 Free PMC article. Review.
Cited by
-
Roles and Regulation of BCL-xL in Hematological Malignancies.Int J Mol Sci. 2022 Feb 16;23(4):2193. doi: 10.3390/ijms23042193. Int J Mol Sci. 2022. PMID: 35216310 Free PMC article. Review.
-
NADPH oxidase 4 regulates anoikis resistance of gastric cancer cells through the generation of reactive oxygen species and the induction of EGFR.Cell Death Dis. 2018 Sep 20;9(10):948. doi: 10.1038/s41419-018-0953-7. Cell Death Dis. 2018. PMID: 30237423 Free PMC article.
-
MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer.Drug Dev Res. 2015 Sep;76(6):328-42. doi: 10.1002/ddr.21270. Epub 2015 Aug 18. Drug Dev Res. 2015. PMID: 26284568 Free PMC article. Review.
-
KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth.Oncogene. 2017 Jun 8;36(23):3322-3333. doi: 10.1038/onc.2016.481. Epub 2017 Jan 9. Oncogene. 2017. PMID: 28068326 Free PMC article.
-
Whole exome sequencing of multiple meningiomas with varying histopathological presentation in one patient revealed distinctive somatic mutation burden and independent clonal origins.Cancer Manag Res. 2019 May 6;11:4085-4095. doi: 10.2147/CMAR.S202394. eCollection 2019. Cancer Manag Res. 2019. PMID: 31123420 Free PMC article.
References
-
- Jiang J, Chan YS, Loh YH, Cai J, Tong GQ, Lim CA, et al. A core Klf circuitry regulates self-renewal of embryonic stem cells. Nat Cell Biol. 2008;10:353–360. - PubMed
-
- Aksoy I, Giudice V, Delahaye E, Wianny F, Aubry M, Mure M, et al. Klf4 and Klf5 differentially inhibit mesoderm and endoderm differentiation in embryonic stem cells. Nat Commun. 2014;5:3719. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P20 RR016440/RR/NCRR NIH HHS/United States
- S10RR026378/RR/NCRR NIH HHS/United States
- P30 CA125123/CA/NCI NIH HHS/United States
- P30 RR032138/RR/NCRR NIH HHS/United States
- P20 RR016477/RR/NCRR NIH HHS/United States
- P20GM103434/GM/NIGMS NIH HHS/United States
- P30GM103488/GM/NIGMS NIH HHS/United States
- S10 RR026378/RR/NCRR NIH HHS/United States
- S10 RR020866/RR/NCRR NIH HHS/United States
- P20 GM103434/GM/NIGMS NIH HHS/United States
- P30 GM103488/GM/NIGMS NIH HHS/United States
- P30 RR032138/GM103488/GM/NIGMS NIH HHS/United States
- R01 CA127405/CA/NCI NIH HHS/United States
- RR020866/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous